MedTrace Logo

CDP-choline Treatment in ATS Users

NCT02630069 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-08-01

No results posted yet for this study

Summary

This study is a 12-week, randomized, double-blind, placebo-controlled trial of cytidine-5'-diphosphate choline in amphetamine-type stimulants-using adolescents.

Conditions

Interventions

DRUG

CDP-choline

CDP-choline 500mg once a day for 12 weeks

DRUG

Placebo

Placebo 500mg once a day for 12 weeks

BEHAVIORAL

Supportive psychotherapy

Supportive psychotherapy 1 session/2 weeks for 12 weeks

Sponsors & Collaborators

  • Ewha Womans University Mokdong Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02630069 on ClinicalTrials.gov